Relevant bibliographies by topics / RANK ligand inhibitor

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers
  5. Reports

Academic literature on the topic 'RANK ligand inhibitor'

Author: Grafiati
Published: 2 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'RANK ligand inhibitor.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "RANK ligand inhibitor"

1

Ikhena, Deborah E., Shimeng Liu, Stacy Kujawa, et al. "RANKL/RANK Pathway and Its Inhibitor RANK-Fc in Uterine Leiomyoma Growth." Journal of Clinical Endocrinology & Metabolism 103, no. 5 (2018): 1842–49. http://dx.doi.org/10.1210/jc.2017-01585.

Full text
Abstract:
Abstract Context Uterine leiomyomas are the most common type of gynecologic tumor in women. Objective To determine the role of the cytokine receptor activator of nuclear factor κ-Β ligand (RANKL); its receptor, receptor activator of nuclear factor κ-Β (RANK); and the RANKL/RANK pathway inhibitor RANK-Fc in leiomyoma growth. Design Messenger RNA (mRNA) or protein levels of RANKL, RANK, and proliferation markers cyclin D1 and Ki67 were assessed in various leiomyoma tissues and cell populations. Human xenograft experiments were performed to determine the effects of RANK-Fc on leiomyoma growth in
APA, Harvard, Vancouver, ISO, and other styles
2

Sutton, Emily E., and Daniel M. Riche. "Denosumab, a RANK Ligand Inhibitor, for Postmenopausal Women with Osteoporosis." Annals of Pharmacotherapy 46, no. 7-8 (2012): 1000–1009. http://dx.doi.org/10.1345/aph.1q543.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Passaponti, Sofia, Leonardo Ermini, Giulia Acconci, et al. "Rank-Rankl-Opg Axis in Multiple Sclerosis: The Contribution of Placenta." Cells 11, no. 8 (2022): 1357. http://dx.doi.org/10.3390/cells11081357.

Full text
Abstract:
Women with multiple sclerosis (MS) can safely become pregnant and give birth, with no side effects or impediments. Pregnancy is generally accepted as a period of well-being in which relapses have a softer evolution, particularly in the third trimester. Herein, we hypothesized that the placenta, via its “secretome”, could contribute to the recognized beneficial effects of pregnancy on MS activity. We focused on a well-known receptor/ligand/decoy receptor system, such as the one composed by the receptor activator of nuclear factor-kB (RANK), its ligand (RANKL), and the decoy receptor osteoproteg
APA, Harvard, Vancouver, ISO, and other styles
4

Liu, Huan, Ning-Yu Ru, Yue Cai та ін. "The OPG/RANKL/RANK system modulates calcification of common carotid artery in simulated microgravity rats by regulating NF-κB pathway". Canadian Journal of Physiology and Pharmacology 100, № 4 (2022): 324–33. http://dx.doi.org/10.1139/cjpp-2021-0329.

Full text
Abstract:
Functional and structural adaptation of common carotid artery could be one of the important causes of postflight orthostatic intolerance after microgravity exposure, the mechanisms of which remain unclear. Recent evidence indicates that long-term spaceflight increases carotid artery stiffness, which might present a high risk to astronaut health and postflight working ability. Studies have suggested that vascular calcification is a common pathological change in cardiovascular diseases that is mainly manifested as an increase in vascular stiffness. Therefore, this study investigated whether simu
APA, Harvard, Vancouver, ISO, and other styles
5

Kiss, Emese, Zénó Kuluncsics, Zoltán Kiss, and Gyula Poór. "Biotechnological advances in monoclonal antibody therapy: the RANK ligand inhibitor antibody." Orvosi Hetilap 151, no. 52 (2010): 2137–44. http://dx.doi.org/10.1556/oh.2010.29010.

Full text
Abstract:
Biológiai gyógyszereket a múlt század közepe óta használ az orvostudomány. Napjainkban szemtanúi lehetünk intenzív fejlődésüknek és elterjedésüknek a klinikai gyakorlatban. Eddig 350 millió beteg részesült a forgalomban lévő körülbelül 250 biológiai terápia valamelyikében. Biológiai készítmények közé sorolandóak a fehérjetermészetű makromolekulák, amelyeknek tömeges gyártását a biotechnológia tette lehetővé. E gyártási modell fogalmát, amely során élő szervezeteket használnak fel a termelésben, magyar mérnök, Ereky Károly vezette be. A szerzők jelen összefoglalóban elsősorban a biotechnológiai
APA, Harvard, Vancouver, ISO, and other styles
6

Kerboua, Esma. "Place of rank ligand inhibitor in giant cell tumour of bone." Journal of Clinical Oncology 42, no. 16_suppl (2024): e23511-e23511. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e23511.

Full text
Abstract:
e23511 Background: Giant cell tumour of bone (GCTB) is a locally aggressive and osteolytic tumour.The peak incidence is during the third and fourth decades of life. The majority of tumours occur in the metaepiphyseal (end) region of the long bones. Surgical resection is the preferred treatment option, if possible but it is a tumor which always poses progressive problems. Denosumab is indicated in recurrent or unresectable GCTB. Methods: We report a series of 70 patients treated for GCT at the medical oncology department of the CPMC (Algiers) in collaboration with the orthopedics department of
APA, Harvard, Vancouver, ISO, and other styles
7

Li, Xiaodong, Michael S. Ominsky, Marina Stolina, et al. "Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin." Bone 45, no. 4 (2009): 669–76. http://dx.doi.org/10.1016/j.bone.2009.06.011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tsourdi, Elena, Tilman D. Rachner, Martina Rauner, Christine Hamann, and Lorenz C. Hofbauer. "Denosumab for bone diseases: translating bone biology into targeted therapy." European Journal of Endocrinology 165, no. 6 (2011): 833–40. http://dx.doi.org/10.1530/eje-11-0454.

Full text
Abstract:
Signalling of receptor activator of nuclear factor-κB (RANK) ligand (RANKL) through RANK is a critical pathway to regulate the differentiation and activity of osteoclasts and, hence, a master regulator of bone resorption. Increased RANKL activity has been demonstrated in diseases characterised by excessive bone loss such as osteoporosis, rheumatoid arthritis and osteolytic bone metastases. The development and approval of denosumab, a fully MAB against RANKL, has heralded a new era in the treatment of bone diseases by providing a potent, targeted and reversible inhibitor of bone resorption. Thi
APA, Harvard, Vancouver, ISO, and other styles
9

Fessler, Beate. "Knochenmetastasen beim fortgeschrittenen Mammakarzinom: Risiko Skelett-bezogener Ereignisse senken." Onkologische Welt 03, no. 01 (2012): 34. http://dx.doi.org/10.1055/s-0038-1631070.

Full text
Abstract:
Knochenmetastasen sind eine häufige Komplikation bei Frauen mit fortgeschrittenem Mammakarzinom. Mit dem RANK-Ligand-Inhibitor Denosumab (XGEVA®) lässt sich die Dauer bis zum Auftreten des ersten Skelett-bezogenen Ereignisses (SRE) im Vergleich zur Standardtherapie verzögern.
APA, Harvard, Vancouver, ISO, and other styles
10

Kwon, H. S., J. Y. Kim, S. U. Kim, et al. "AB0055 THE ROLES OF OX40L AND TNF BISPECIFIC ANTIBODY IN OSTEOCLASTOGENESIS." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1206.2–1207. http://dx.doi.org/10.1136/annrheumdis-2023-eular.5450.

Full text
Abstract:
BackgroundRheumatoid arthritis (RA) is a chronic, inflammatory disease that leads to progressive cartilage and bone destruction. OX40 ligand (OX40L) is expressed predominantly on antigen-presenting cells and highly associated with joint inflammation in RA[1]. Yet, the role of OX40L in osteoclastogenesis is unclear.ObjectivesIn this study, we investigated the effects of dual blocking of TNF and OX40L by bispecific antibody (IMB-101) on RANKL-induced osteoclastogenesis.MethodsCD14+ monocytes were isolated from peripheral blood mononuclear cells (PBMCs) of healthy donors (n=6). CD14+ monocytes we
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "RANK ligand inhibitor"

1

Chypre, Mélanie. "Role of receptor activator of NF-kB ligand (RANKL) in adult lymph node homeostasis and identification of inhibitors." Thesis, Strasbourg, 2017. http://www.theses.fr/2017STRAJ016/document.

Full text
Abstract:
Le récepteur activateur de NF-κB (RANK), membre de la famille des récepteurs au TNF, est connu pour son rôle dans l’homéostasie de l’os, mais joue aussi un rôle important dans le système immunitaire. J’ai tout d’abord étudié des outils permettant de cibler RANK/RANKL. J’ai caractérisé et comparé l’activité biologique de deux anticorps anti-RANK. J’ai également criblé une librairie de petites molécules pour identifier des inhibiteurs de l’interaction RANK/RANKL. Dans une deuxième partie, je me suis intéressée au rôle du ligand de RANK (RANKL) dans l’homéostasie du ganglion lymphatique. RANKL jo
APA, Harvard, Vancouver, ISO, and other styles
2

Gendron, Steve. "Régulation de la survie et des fonctions ostéoclastogéniques des lymphocytes T par les intégrines liant le collagène." Thesis, Université Laval, 2009. http://www.theses.ulaval.ca/2009/26670/26670.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Tseng, Huan-Hung, and 曾煥鴻. "NC-8 inhibits RANK ligand induced osteoclast differentiation from Monocyte/ Macrophages Lineage precursor cell." Thesis, 2015. http://ndltd.ncl.edu.tw/handle/53676034659658974940.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Shakibaei, M., C. Buhrmann, and A. Mobasheri. "Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-kappaB ligand (RANKL) activation of NF-kappaB signaling and inhibit osteoclastogenesis in bone-derived cells." 2011. http://hdl.handle.net/10454/6182.

Full text
Abstract:
Resveratrol is a polyphenolic phytoestrogen that has been shown to exhibit potent anti-oxidant, anti-inflammatory, and anti-catabolic properties. Increased osteoclastic and decreased osteoblastic activities result in bone resorption and loss of bone mass. These changes have been implicated in pathological processes in rheumatoid arthritis and osteoporosis. Receptor activator of NF-kappaB ligand (RANKL), a member of the TNF superfamily, is a major mediator of bone loss. In this study, we investigated the effects of resveratrol on RANKL during bone morphogenesis in high density bone cultures in
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "RANK ligand inhibitor"

1

Hamdy, Ronald C. "Receptor activator of nuclear factor kappa-B ligand (RANK-L) inhibitor—Denosumab." In Diagnosis and Treatment of Osteoporosis. Elsevier, 2024. http://dx.doi.org/10.1016/b978-0-323-99550-4.00004-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kulenovic, Adnan, and Azra Lagumdzija-Kulenovic. "Minimizing STOPP and Beers Criteria Risks in PIM Treatments Using PM-TOM and ChatGPT: A Case Study." In Studies in Health Technology and Informatics. IOS Press, 2025. https://doi.org/10.3233/shti250067.

Full text
Abstract:
PM-TOM (Personalized Medicine-Therapy Optimization Method) is a clinical decision-support tool designed to optimize polypharmacy treatments by minimizing their adverse drug reactions (ADRs) caused by individual drugs or drug interactions (DDIs, DCIs, DFIs, DGIs), along with the risks identified by the STOPP and Beers criteria. On the other hand, AI tools like ChatGPT 4.0, trained on medical literature texts, can provide broader clinical reasoning and insights tailored to individual patient contexts. By referring to a documented deprescribing case, this study demonstrates the synergistic power
APA, Harvard, Vancouver, ISO, and other styles
3

Hecht, Keith A. "Bone-Directed Therapy for Metastatic Cancer." In Pain. Oxford University Press, 2022. http://dx.doi.org/10.1093/med/9780197542873.003.0031.

Full text
Abstract:
Bone is one of the most common sites of metastases in patients with advanced cancer. Bone metastases are painful for patients and can result in clinical consequences such as fractures. In addition to systemic analgesics, other treatment options are useful in the management of patients with bone metastases, such as radiation therapy and bone-modifying agents. Single-fraction external beam radiation therapy is the most effective bone-directed therapy for treating single location pain from skeletal metastases. Systemic radiation therapy using radiopharmaceuticals should be considered in patients
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "RANK ligand inhibitor"

1

Nguyen, Bastien, Marion Maetens, Roberto Salgado, et al. "Abstract CT101: D-BEYOND: A window of opportunity trial evaluating denosumab, a RANK-ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-ct101.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kushlinskii, N. E., E. S. Gershtein, Yu S. Timofeev, et al. "RECEPTOR ACTIVATOR OF NUCLEAR TRANSCRIPTION FACTOR NF-B (RANK), ITS LIGAND (RANKL) AND NATURAL INHIBITOR OSTEOPROTEGERIN (OPG) IN BLOOD SERUM OF PRIMARY BONE TUMOR PATIENTS: ASSOCIATION WITH CLINICOPATHOLOGICAL FEATURES AND INFLAMMATORY CYTOKINES LEVELS." In RAD Conference. RAD Association, 2017. http://dx.doi.org/10.21175/radproc.2017.51.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Chhibar, PS, and G. Ehresmann. "AB0852 Increased infection rate with concomitant rank ligand inhibitor denosumab and biologic therapies for rheumatic diseases: reality or illusion? experience with 40 patients over 66 months at the university of southern california." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.1140.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Nguyen, B., M. Marion, R. Salgado, et al. "Abstract PD5-06: The immunomodulatory potential of denosumab in breast cancer: results from D-BEYOND, a window of opportunity trial evaluating a RANK-ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer." In Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-pd5-06.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Almeida Filho, João L. de, and Jorge H. Fernandez. "HTP SurflexDock: a web tool for Structure-Based Virtual Screening analysis based on the Ensemble Docking protocol." In Brazilian e-Science Workshop. Sociedade Brasileira de Computação - SBC, 2022. http://dx.doi.org/10.5753/bresci.2022.223295.

Full text
Abstract:
Structure-Based Virtual Screening (SVBS) is a technique traditionally used to find a set of specific inhibitors for a receptor structure during the preliminary stages of drug discovery studies. However, more than 90% of SBVS best ranks compounds do not have the expected biological effect at the end of the process. In this context, strategies to increase the success rate must be employed to ensure the experiment's success. Here, we introduce the HTP SurflexDock, a tool that improves the success rate of SBVS experiments through two strategies: First, the ensemble docking protocol enables the sim
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "RANK ligand inhibitor"

1

Pavasant, Prasit, and Tussanee Yongchaitrakul. Influence of mechanical stress on the expression of osteopontin in human periodontal ligament cells. Chulalongkorn University, 2008. https://doi.org/10.58837/chula.res.2008.14.

Full text
Abstract:
Background: Mechanical stress such as orthodontic forces can produce mechanical damage and inflammatory reaction in periodontium. Osteopontin (OPN) is a multifunctional cytokine that found to be correlated with periodontal disease progression. As periodontal ligaments (PDL) can be affected by stress and PDL cells are involved in periodontal destruction and remodeling, we aimed to investigate the influence of mechanical stress on the expression and regulation of OPN in human PDL (HPDL) cells. Methods: The mechanical stress was generated by continuous compressive force and the expression of OPN
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'RANK ligand inhibitor' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography